On June 1, Eli Lilly’s Olumiant (baricitinib) 2mg tablets received FDA approval for adult patients with moderately to severely active rheumatoid arthritis (RA) following a complete response letter from the FDA the previous year. Olumiant marks the second oral janus kinase (JAK) inhibitor to launch for RA in the US market following the launch of Pfizer’s Xelajnz (tofacitinib) in November 2012. The FDA approval for Olumiant comes with a boxed warning for the risk of serious infections, malignancies, and thrombosis; it also requires that patients have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitor therapies, posing a potential marketing challenge for Eli Lilly.

Olumiant will face competition from not only Xeljanz, but also AbbVie’s upadacitinib and Gilead/Galapagos’ filgotinib, both of which have met all primary endpoints in their Phase III trials. Upadactinib and filgotinib specifically inhibit JAK1, offering a better safety profile than either Olumiant or Xelajnz, marking a potential driver for AbbVie and Gilead/Galapagos. However, GlobalData expects upadactinib and filgotinib to launch at least two years after Olumiant in the US, in 2020 and 2021, respectively. As it will only compete with Xeljanz in the immediate future, GlobalData anticipates that Olumiant will establish itself in the RA market, generating sales of $768.9M in 2025 in the US, as seen in Figure 1.

Related Reports

For more insight and data, visit the GlobalData Report Store – Pharmaceutical Technology is part of GlobalData Plc.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.